$DKL

Delek Logistics Partners Q2 Earnings Call Highlights

Delek Logistics Partners (NYSE: DKL) reported Q2 results on its earnings call. Gas volumes rose to over 80 million cubic feet per day from about 64 million in Q1, and Delaware crude volumes exceeded 157,000 bpd. Gathering and processing adjusted EBITDA was $104 million. DCF was about $81 million and the board raised the quarterly distribution to $1.135 per unit.

Original reporting
Published Aug 8, 2026, 4:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 4:55 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Delek Logistics Partners Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$DKLBullishMed
01

Why it matters

The combination of record Delaware crude volumes, higher gas and produced-water throughput, a higher quarterly distribution, and a defined growth-capital-to-run-rate EBITDA path provides actionable updates for cash-flow and credit-risk modeling.

02

Market read

Traders can update DKL’s near-term cash-flow expectations using the raised distribution, DCF coverage, and the stated 2026-2027 run-rate EBITDA ramp from growth capital.

03

What to watch

Leverage is modestly higher at 4.23x and management expects managing around 4x while growth projects mature, which can increase sensitivity to commodity price volatility.

Relevance 7/10Novelty 6/10Timing: post-earnings call, pre-market today

Background

The piece summarizes Delek Logistics Partners’ Q2 earnings call, focusing on volumes, segment adjusted EBITDA, capital spending, distribution, and leverage/refinancing actions.

Company-level read

Ticker impact

$DKLBullishMedium confidence
Context

Delek Logistics reported Q2 adjusted EBITDA of $104M, raised its quarterly distribution to $1.135/unit, and guided growth capital to drive run-rate EBITDA.

Expected impact

Near-term bias positive as distribution increase and run-rate EBITDA targets support cash-flow expectations, though leverage near 4x may cap upside.

Evidence & confidence

The article provides concrete Q2 segment EBITDA, DCF coverage, distribution increase, and a full-year growth capital and run-rate EBITDA framework, which are direct inputs to valuation and risk for DKL.

Market effects

Supports the view that Permian midstream sour-gas and integrated gathering demand is strengthening, potentially benefiting peers with similar processing exposure.

Highlights continued Northern Delaware activity and Waha-linked gas pricing support, reinforcing Permian basin throughput expectations.

Limited direct global linkage, but crude and gas volume strength can marginally influence sentiment toward US energy infrastructure.

Counterpoint

Higher volumes may not translate 1:1 into sustained margins if realized pricing or sour-gas ramp costs underperform the run-rate EBITDA plan.

Key entities

  • Delek Logistics Partners L.P.

    Master limited partnership reporting Q2 operating metrics, distribution increase, and growth capital/run-rate EBITDA expectations.

  • Robert Wright

    CFO cited drivers of segment adjusted EBITDA changes and refinancing impacts.

  • Mohit Bhardwaj

    EVP new energy, strategy and investor relations discussed Waha pricing and EBITDA contribution timing.

Related articles

$DKLMedAI 8/10

Delek Logistics Partners, LP Q2 2026 Earnings Call Summary

Delek Logistics Partners (DKL) reported record Q2 2026 adjusted EBITDA of $144 million, citing higher Delaware crude volumes and improved Libby gas utilization. It reaffirmed full-year 2026 adjusted EBITDA guidance of $520 million to $560 million, announced a $1.135 per-unit distribution, issued $800 million senior notes, and discussed growth from sour gas and produced-water services.

$DKLMed

Delek Logistics Partners, LP (DKL): Results of Operations and Financial Condition

Delek Logistics Partners, LP (DKL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dkl-ex991xearningsreleasex.htm EX-99.1 Document Exhibit 99.1 Delek Logistics Reports Second Quarter 2026 Results • Delek Logistics reported net income of $28.9 million or $0.54 per unit, and adjusted EBITDA of $143.5 million • Nearing completion of the integrated sour g

$CVXMed

3 Energy Stocks Built to Last a Lifetime and Pay You the Whole Way

The article highlights energy stocks with higher dividend yields than the S&P 500’s ~1.1%. It cites the S&P Energy Select Sector index yield of 2.7% and notes 69 U.S.-listed energy stocks yield at least 3%. It spotlights Chevron (3.78% yield; 39 straight dividend increases; Q1 shareholder rewards $6B), Delek Logistics (8.76% yield; April payout increase; 23.7% YoY earnings growth; plans to source 80% of 2026 EBITDA from third parties), and Kinetik (6.3% yield; reiterated 2026 EBITDA guidance; bu

$CVXMed

3 Energy Stocks Built to Last a Lifetime and Pay You the Whole Way

The article highlights energy as an S&P 500 sector with higher dividend yields, citing a 2.7% yield for the S&P Energy Select Sector index. It spotlights Chevron (3.7% yield; 39 straight dividend increases; Q1 shareholder rewards $6B), Delek Logistics (8.8% yield; April payout increase; 23.7% YoY earnings growth; expects 80% of 2026 EBITDA from third parties), and Kinetik (6.3% yield; reiterated 2026 EBITDA guidance).

$DLXMed

Deluxe Q2 Earnings Call Highlights

Deluxe (NYSE:DLX) reported Q2 segment results, led by Data Solutions revenue up 21.4% to $82.3M and adjusted EBITDA of $18.1M. Merchant Services revenue rose 6.1% to $107.6M. Print revenue fell 4.3% to $235.9M. Deluxe closed its Celero acquisition on July 31 and raised 2026 guidance: revenue $2.095B-$2.12B, adj. EBITDA $455M-$475M, adj. EPS $3.60-$4.00, and FCF about $200M.

$NEOGMedAI 8/10

Neogen (NEOG) Q4 2026 Earnings Call Transcript

Neogen (NEOG) reported fiscal Q4 2026 revenue of $225.3 million, up 4.3% in core growth, led by Food Safety. Adjusted gross margin rose to 49.7% and adjusted EBITDA grew 12% to $45.4 million. FY2027 guidance: revenue $880-$885 million and adjusted EBITDA $180-$182 million. The company plans a 50% R&D increase and a $140 million genomics divestiture for debt reduction.